Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | YAP1 | P46937 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787967 | 0.91 | PPARG (0.67) | PPARG | |
| SCHEMBL7708713 | 0.86 | PPARG (0.51) | PPARG | |
| SCHEMBL7922605 | 0.84 | PPARG (0.56) | PPARGLTA4HYAP1RAB9AGAA | |
| SCHEMBL7708712 | 0.84 | PPARG (0.60) | PPARG | |
| SCHEMBL27532922 | 0.83 | PPARG (0.53) | PPARGRAB9AMEN1NPC1KMT2A | |
| SCHEMBL8457042 | 0.81 | PPARG (0.51) | PPARGRAB9AGAA | |
| SCHEMBL2788893 | 0.79 | PPARG (0.58) | PPARGLTA4HYAP1RAB9AGAA | |
| SCHEMBL3499760 | 0.76 | LTA4H (0.65) | PPARGLTA4HYAP1RAB9AGAA | |
| SCHEMBL3499757 | 0.76 | LTA4H (0.65) | PPARGLTA4HYAP1RAB9AGAA | |
| SCHEMBL13110180 | 0.76 | LTA4H (0.65) | PPARGLTA4HYAP1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6294580-B1 | FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE | GLAXO WELLCOME INC. | 2001-09-25 | — | — | US | disclosed |
| EP-0888317-B1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LTD (GB) | 2001-09-12 | — | — | EP | disclosed |
| EP-0888317-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031907-A1 | SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA | GLAXO GROUP LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |